Journal of Clinical Endocrinology & Metabolism, Vol 71, 764-769, Copyright © 1990 by Endocrine Society

ARTICLES

The use and limitations of a chemiluminescent thyrotropin assay as a single thyroid function test in an out-patient endocrine clinic

DS Ross, GH Daniels and D Gouveia
Department of Medicine, Massachusetts General Hospital, Boston 02114.

A chemiluminescent TSH assay (detection limit, less than 0.01 mU/L) allows for accurate measurement of subnormal TSH concentrations. We retrospectively analyzed serum TSH and the free T4 (fT4) index of 460 consecutive endocrine clinic visits to determine the usefulness of TSH measurements alone in the assessment of thyroid function. Additionally, case histories were presented nonconsecutively to one of us (TSH alone or TSH with fT4) to determine if knowledge of the fT4 level would alter management. Of hypothyroid patients on replacement therapy (n = 127), 60% had concordant fT4 and TSH, 14% had subnormal TSH with normal fT4, 18% had high TSH with normal fT4, and 4% normal TSH with high fT4; only 4% were managed differently when the fT4 level was known in addition to TSH. Of the patients receiving suppressive therapy with TSH levels above 0.05 mU/L (n = 81), only 4% were managed differently when fT4 was known; 4% had high fT4. With TSH levels below 0.05 mU/L (n = 64), knowledge of fT4 was felt to be necessary for management in all cases; 53% had high fT4. Twenty-three of 46 (50%) patients being treated for hyperthyroidism had discordant TSH and fT4, including 7 patients with low TSH and low fT4. Two of 21 (10%) patients screened with pituitary/hypothalamic disease had discordant TSH and fT4, and 4 of 9 (44%) patients treated with L-T4 for secondary hypothyroidism had subnormal TSH. Knowledge of fT4 was felt to be necessary in all these cases. We conclude that TSH alone is sufficient for screening and monitoring L-T4 replacement or suppression therapy if TSH levels are above 0.05 mU/L. These patients account for the majority of visits to our endocrine clinic. TSH alone is misleading in pituitary disease and during the treatment of hyperthyroidism. fT4 is needed if TSH levels are less than 0.05 mU/L to assess the degree of hyperthyroidism.

This article has been cited by other articles:

				O. M. Dekkers, N. R. Biermasz, A. M. Pereira, F. Roelfsema, M. O. van Aken, J. H. C. Voormolen, and J. A. Romijn Mortality in Patients Treated for Cushing's Disease Is Increased, Compared with Patients Treated for Nonfunctioning Pituitary Macroadenoma J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 976 - 981. [Abstract] [Full Text] [PDF]

				G Brabant, P Beck-Peccoz, B Jarzab, P Laurberg, J Orgiazzi, I Szabolcs, A P Weetman, and W M Wiersinga Is there a need to redefine the upper normal limit of TSH? Eur. J. Endocrinol., May 1, 2006; 154(5): 633 - 637. [Abstract] [Full Text] [PDF]

				F Azizi, L Ataie, M Hedayati, Y Mehrabi, and F Sheikholeslami Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine Eur. J. Endocrinol., May 1, 2005; 152(5): 695 - 701. [Abstract] [Full Text] [PDF]

				M. I. Surks, E. Ortiz, G. H. Daniels, C. T. Sawin, N. F. Col, R. H. Cobin, J. A. Franklyn, J. M. Hershman, K. D. Burman, M. A. Denke, et al. Subclinical Thyroid Disease: Scientific Review and Guidelines for Diagnosis and Management JAMA, January 14, 2004; 291(2): 228 - 238. [Abstract] [Full Text] [PDF]

				N. F. Col, M. I. Surks, and G. H. Daniels Subclinical Thyroid Disease: Clinical Applications JAMA, January 14, 2004; 291(2): 239 - 243. [Abstract] [Full Text] [PDF]

				L. J. S. Brokken, W. M. Wiersinga, and M. F. Prummel Thyrotropin Receptor Autoantibodies Are Associated with Continued Thyrotropin Suppression in Treated Euthyroid Graves' Disease Patients J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4135 - 4138. [Abstract] [Full Text] [PDF]

				B. Biondi, E. A. Palmieri, G. Lombardi, and S. Fazio Effects of Subclinical Thyroid Dysfunction on the Heart Ann Intern Med, December 3, 2002; 137(11): 904 - 914. [Abstract] [Full Text] [PDF]

				J. L. Johnson and D. S. Duick Diabetes and Thyroid Disease: A Likely Combination Diabetes Spectr, July 1, 2002; 15(3): 140 - 142. [Full Text] [PDF]

				J. W. Chu and L. M. Crapo The Treatment of Subclinical Hypothyroidism Is Seldom Necessary J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4591 - 4599. [Full Text] [PDF]

				L. J. S. Brokken, J. W. C. Scheenhart, W. M. Wiersinga, and M. F. Prummel Suppression of Serum TSH by Graves' Ig: Evidence for a Functional Pituitary TSH Receptor J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4814 - 4817. [Abstract] [Full Text] [PDF]

				M. F. Prummel, L. J. S. Brokken, G. Meduri, M. Misrahi, O. Bakker, and W. M. Wiersinga Expression of the Thyroid-Stimulating Hormone Receptor in the Folliculo-Stellate Cells of the Human Anterior Pituitary J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4347 - 4353. [Abstract] [Full Text]

				G. J. Canaris, N. R. Manowitz, G. Mayor, and E. C. Ridgway The Colorado Thyroid Disease Prevalence Study Arch Intern Med, February 28, 2000; 160(4): 526 - 534. [Abstract] [Full Text] [PDF]

				C. T. Sawin, A. Geller, P. A. Wolf, A. J. Belanger, E. Baker, P. Bacharach, P. Wilson, E. J. Benjamin, and R. B. D'Agostino Low Serum Thyrotropin Concentrations as a Risk Factor for Atrial Fibrillation in Older Persons N. Engl. J. Med., November 10, 1994; 331(19): 1249 - 1252. [Abstract] [Full Text]

				J. A. Franklyn The Management of Hyperthyroidism N. Engl. J. Med., June 16, 1994; 330(24): 1731 - 1738. [Full Text]